Quick Takeaways
- Gary A. Lyons has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $20,245,398.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Gary A. Lyons
- Location
- San Diego, CA
- Summary
- The estimated net worth of Gary A. Lyons is at least $20,245,398 dollars as of 04 Dec 2025. Gary A. Lyons is the Director of NEUROCRINE BIOSCIENCES INC and owns shares of NEUROCRINE BIOSCIENCES INC (NBIX) stock worth about $18.39M. Gary A. Lyons is the Director of Travere Therapeutics, Inc. and owns shares of Travere Therapeutics, Inc. (TVTX) stock worth about $1.05M. Gary A. Lyons is the Director of Eledon Pharmaceuticals, Inc. and owns shares of Eledon Pharmaceuticals, Inc. (ELDN) stock worth about $674K. Gary A. Lyons is the Director of RIGEL PHARMACEUTICALS INC and owns shares of RIGEL PHARMACEUTICALS INC (RIGL) stock worth about $131.2K.
- Signature
- /s/ Darin Lippoldt, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Gary A. Lyons and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: NEUROCRINE BIOSCIENCES INC ($18,386,215).
- Past-year value change for that position: -$2,289,083.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Gary A. Lyons
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | Director | $18,386,215 | -$2,289,083 | -11% | 03 Dec 2025 |
| TVTX | Travere Therapeutics, Inc. | Director | $1,053,975 | 15 May 2025 | ||
| ELDN | Eledon Pharmaceuticals, Inc. | Director | $673,958 | 01 May 2023 | ||
| RIGL | RIGEL PHARMACEUTICALS INC | Director | $131,250 | 26 May 2023 | ||
| FRTX | Brickell Biotech, Inc. | Director | 17 May 2022 |
Insider Transactions Reported by Gary A. Lyons:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.